search
Back to results

Effects of Lactobacillus Plantarum PS128 in Children With ASD

Primary Purpose

Autism Spectrum Disorder

Status
Recruiting
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
PS128
Placebo
Sponsored by
Chang Gung Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Autism Spectrum Disorder

Eligibility Criteria

7 Years - 12 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • (1) Age 7 to 12 years old.
  • (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule.
  • (3) Normal control group: Children without autism spectrum disorder.

Exclusion Criteria:

  • (1) Receiving antibiotics within one month.
  • (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods).
  • (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy)
  • (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet).
  • (5) Those with a history of cancer.
  • (6) Those who are allergic to lactic acid bacteria.
  • (7) Not eligible judged by PI

Sites / Locations

  • Chang Gung Memorial HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Placebo Comparator

No Intervention

Arm Label

PS128

Placebo

Normal control

Arm Description

Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.

Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.

Normal control group are enrolled by invitation from the age and gender matched healthy children.

Outcomes

Primary Outcome Measures

Changes of total scores of Social Responsiveness Scale
Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness.

Secondary Outcome Measures

Changes of total scores of Repetitive Behavior Scale-Revised
Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior.
Changes of total scores of Child Behavior Checklist
Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The lower scores stand for better behavioral and emotional regulation.
Changes of total scores of Adaptive Behavior Assessment System
Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior.
Changes in accuracy of Frith-Happe animation
A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition.
Changes in accuracy of Eyes task
An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills.
Changes of total scores of Aberrant Behavior Checklist
Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The lower scores stand for less aberrant behavior.
Visual Analogue Scale for GI symptoms
Visual Analogue Scale for GI symptoms was designed to measure the response of symptoms and well-being in patients after taking PS128. The score ranges from 0-10. The lower scores stand for less GI symptoms.
Changes of total scores of Emotional Dysregulation Inventory
Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation.
Changes of total scores of Parenting Stress Index, Fourth Editon
Parenting Stress Index is a parents' report questionnaire for parenting stress. The lower scores stand for lower parenting stress.
Assessment of Clinical Global Impression-Severity of Illness
The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.
Assessment of Patient Global Impression of Change
The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
Gut microbiota
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library.
MRI T1
Brain structural volumes (cm²)
functional MRI (resting-state/biological motion task) - BOLD signal
Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity.
Diffusion Tensor Imaging (DTI) - FA
Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons.
Safety assessment - Albumin
Safety is assessed function of liver and kidney such as albumin (6.6-8.7 g/dl).
Safety assessment - Total Protein
Safety is assessed function of liver and kidney such as total protein (3.8-5.3 g/dl).
Safety assessment - ALP
Safety is assessed function of liver and kidney such as ALP (40-129 IU/L).
Safety assessment - Total Bilirubin
Safety is assessed function of liver and kidney such as total bilirubin (0.2-1.2 mg/dl).
Safety assessment - T-Cholesterol
Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL).
Safety assessment - Uric Acid
Safety is assessed function of liver and kidney such as uric acid (3.4-7.6 mg/dl).
Safety assessment - BUN
Safety is assessed function of liver and kidney such as BUN (6-20 mg/dl).
Safety assessment - Creatinine
Safety is assessed function of liver and kidney such as creatinine (0.6-1.3 mg/dl).
Safety assessment - AST
Safety is assessed function of liver and kidney such as AST (8-38 IU/L).
Safety assessment - ALT
Safety is assessed function of liver and kidney such as ALT (4-44 IU/L).
Change in levels of exploratory blood-based biomarkers for inflammatory changes - MPO
Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL)
Change in levels of exploratory blood-based biomarkers for inflammatory changes - IL-1β
Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL)
Change in levels of exploratory blood-based biomarkers for inflammatory changes - TGF-β1
Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL)
Change in levels of exploratory blood-based biomarkers for inflammatory changes - Eotaxin
Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL)
Change in levels of exploratory blood-based biomarkers for inflammatory changes - IL-6
Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL)
Change in levels of exploratory blood-based biomarkers for oxidative stress changes - Serotonin
Oxidative stress is assessed via Serotonin (ng/mL).
Change in levels of exploratory blood-based biomarkers for oxidative stress changes - GABA
Oxidative stress is assessed via GABA (umol/L).
Change in levels of exploratory blood-based biomarkers for oxidative stress changes - Cortisol
Oxidative stress is assessed via Cortisol (nmol/L).

Full Information

First Posted
March 14, 2022
Last Updated
August 29, 2023
Sponsor
Chang Gung Memorial Hospital
Collaborators
Bened Biomedical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05307744
Brief Title
Effects of Lactobacillus Plantarum PS128 in Children With ASD
Official Title
Effects of Lactobacillus Plantarum PS128 in Children With Autism Spectrum Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 15, 2022 (Actual)
Primary Completion Date
July 31, 2025 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chang Gung Memorial Hospital
Collaborators
Bened Biomedical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms. With sufficient amounts, probiotics can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body. These reactions may further promote health, regulate metabolic disease progression and prevent complications. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal and human studies which modulated the levels of neurotransmitters in different brain areas. This study is to evaluate whether the consumption of PS128 can improve the symptoms of patients with ASD. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in school children with ASD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autism Spectrum Disorder

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PS128
Arm Type
Experimental
Arm Description
Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks.
Arm Title
Normal control
Arm Type
No Intervention
Arm Description
Normal control group are enrolled by invitation from the age and gender matched healthy children.
Intervention Type
Dietary Supplement
Intervention Name(s)
PS128
Intervention Description
Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
Primary Outcome Measure Information:
Title
Changes of total scores of Social Responsiveness Scale
Description
Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness.
Time Frame
Baseline, Week 12 and Week 16
Secondary Outcome Measure Information:
Title
Changes of total scores of Repetitive Behavior Scale-Revised
Description
Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior.
Time Frame
Baseline, Week 12 and Week 16
Title
Changes of total scores of Child Behavior Checklist
Description
Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The lower scores stand for better behavioral and emotional regulation.
Time Frame
Baseline, Week 12 and Week 16
Title
Changes of total scores of Adaptive Behavior Assessment System
Description
Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior.
Time Frame
Baseline, week 12 and Week 16W
Title
Changes in accuracy of Frith-Happe animation
Description
A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition.
Time Frame
Baseline, Week 12 and Week 16
Title
Changes in accuracy of Eyes task
Description
An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills.
Time Frame
Baseline, Week 12 and Week 16
Title
Changes of total scores of Aberrant Behavior Checklist
Description
Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The lower scores stand for less aberrant behavior.
Time Frame
Baseline, Week 12 and Week 16
Title
Visual Analogue Scale for GI symptoms
Description
Visual Analogue Scale for GI symptoms was designed to measure the response of symptoms and well-being in patients after taking PS128. The score ranges from 0-10. The lower scores stand for less GI symptoms.
Time Frame
Baseline, week 12 and Week 16
Title
Changes of total scores of Emotional Dysregulation Inventory
Description
Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation.
Time Frame
Baseline, Week 12 and Week 16
Title
Changes of total scores of Parenting Stress Index, Fourth Editon
Description
Parenting Stress Index is a parents' report questionnaire for parenting stress. The lower scores stand for lower parenting stress.
Time Frame
Baseline, Week 12 and Week 16
Title
Assessment of Clinical Global Impression-Severity of Illness
Description
The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse.
Time Frame
Baseline, Week 12 and Week 16
Title
Assessment of Patient Global Impression of Change
Description
The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
Time Frame
Week 12 and Week 16
Title
Gut microbiota
Description
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library.
Time Frame
Baseline and Week 12
Title
MRI T1
Description
Brain structural volumes (cm²)
Time Frame
Baseline and Week 12
Title
functional MRI (resting-state/biological motion task) - BOLD signal
Description
Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity.
Time Frame
Baseline and Week 12
Title
Diffusion Tensor Imaging (DTI) - FA
Description
Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons.
Time Frame
Baseline and Week 12
Title
Safety assessment - Albumin
Description
Safety is assessed function of liver and kidney such as albumin (6.6-8.7 g/dl).
Time Frame
Baseline and Week 12
Title
Safety assessment - Total Protein
Description
Safety is assessed function of liver and kidney such as total protein (3.8-5.3 g/dl).
Time Frame
Baseline and Week 12
Title
Safety assessment - ALP
Description
Safety is assessed function of liver and kidney such as ALP (40-129 IU/L).
Time Frame
Baseline and Week 12
Title
Safety assessment - Total Bilirubin
Description
Safety is assessed function of liver and kidney such as total bilirubin (0.2-1.2 mg/dl).
Time Frame
Baseline and Week 12
Title
Safety assessment - T-Cholesterol
Description
Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL).
Time Frame
Baseline and Week 12
Title
Safety assessment - Uric Acid
Description
Safety is assessed function of liver and kidney such as uric acid (3.4-7.6 mg/dl).
Time Frame
Baseline and Week 12
Title
Safety assessment - BUN
Description
Safety is assessed function of liver and kidney such as BUN (6-20 mg/dl).
Time Frame
Baseline and Week 12
Title
Safety assessment - Creatinine
Description
Safety is assessed function of liver and kidney such as creatinine (0.6-1.3 mg/dl).
Time Frame
Baseline and Week 12
Title
Safety assessment - AST
Description
Safety is assessed function of liver and kidney such as AST (8-38 IU/L).
Time Frame
Baseline and Week 12
Title
Safety assessment - ALT
Description
Safety is assessed function of liver and kidney such as ALT (4-44 IU/L).
Time Frame
Baseline and Week 12
Title
Change in levels of exploratory blood-based biomarkers for inflammatory changes - MPO
Description
Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL)
Time Frame
Baseline and Week 12
Title
Change in levels of exploratory blood-based biomarkers for inflammatory changes - IL-1β
Description
Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL)
Time Frame
Baseline and Week 12
Title
Change in levels of exploratory blood-based biomarkers for inflammatory changes - TGF-β1
Description
Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL)
Time Frame
Baseline and Week 12
Title
Change in levels of exploratory blood-based biomarkers for inflammatory changes - Eotaxin
Description
Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL)
Time Frame
Baseline and Week 12
Title
Change in levels of exploratory blood-based biomarkers for inflammatory changes - IL-6
Description
Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL)
Time Frame
Baseline and Week 12
Title
Change in levels of exploratory blood-based biomarkers for oxidative stress changes - Serotonin
Description
Oxidative stress is assessed via Serotonin (ng/mL).
Time Frame
Baseline and Week 12
Title
Change in levels of exploratory blood-based biomarkers for oxidative stress changes - GABA
Description
Oxidative stress is assessed via GABA (umol/L).
Time Frame
Baseline and Week 12
Title
Change in levels of exploratory blood-based biomarkers for oxidative stress changes - Cortisol
Description
Oxidative stress is assessed via Cortisol (nmol/L).
Time Frame
Baseline and Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: (1) Age 7 to 12 years old. (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule. (3) Normal control group: Children without autism spectrum disorder. Exclusion Criteria: (1) Receiving antibiotics within one month. (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods). (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy) (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet). (5) Those with a history of cancer. (6) Those who are allergic to lactic acid bacteria. (7) Not eligible judged by PI
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hsing-Chang Ni, Dr.
Phone
88633281200
Ext
3815
Email
alanni0918@yahoo.com.tw
Facility Information:
Facility Name
Chang Gung Memorial Hospital
City
Taoyuan
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hsing Chang Ni
Phone
886-3-3281200
Ext
2479
Email
alanni0918@yahoo.com.tw
First Name & Middle Initial & Last Name & Degree
Hsing Chang Ni, MD

12. IPD Sharing Statement

Learn more about this trial

Effects of Lactobacillus Plantarum PS128 in Children With ASD

We'll reach out to this number within 24 hrs